{"id":301844,"date":"2026-10-12T12:20:48","date_gmt":"2026-10-12T06:50:48","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=301844"},"modified":"2026-10-12T12:20:48","modified_gmt":"2026-10-12T06:50:48","slug":"medicines-and-lab-testing-stocks-growth-outlook-picks","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/medicines-and-lab-testing-stocks-growth-outlook-picks\/","title":{"rendered":"3 Medicines and Lab Testing Stocks With a Strong Future Roadmap: Aurobindo Pharma, Lincoln Pharmaceuticals and Suraksha Diagnostic"},"content":{"rendered":"

Aurobindo Pharma Rs 1,693.00, P\/E 25.46. Lincoln Pharma Rs 558.30, P\/E 11.64. Suraksha Diagnostic Rs 316.25, P\/E 46.05. Closing prices of 9 Oct 2026.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Medicines and lab testing stocks with the clearest long-term roadmaps today include Aurobindo Pharma in generic formulations and active ingredients, Lincoln Pharma in formulations for India and emerging markets and Suraksha Diagnostic in pathology and diagnostic testing. FY26 revenue growth was 5.6% at Aurobindo Pharma, 9.1% at Lincoln Pharma and 22.5% at Suraksha Diagnostic. P\/E stands at 25.46 for Aurobindo Pharma (industry 37.59), 11.64 for Lincoln Pharma (industry 37.59) and 46.05 for Suraksha Diagnostic (industry 62.79). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.<\/p>\n<\/p><\/div>\n

Medicines and lab testing stocks give investors exposure to medicines, ingredients and lab tests that families and doctors use every day. Volume growth, product mix and margins decide how much of that demand turns into profit.<\/p>\n

This list covers three medicines and lab testing stocks: Aurobindo Pharma for generic formulations and active ingredients, Lincoln Pharmaceuticals for formulations for India and emerging markets and Suraksha Diagnostic for pathology and diagnostic testing. Every figure comes from the latest reported financials and the 9 October 2026 market close. Companies without complete current figures were left out.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n